Berberine: A Promising Natural Isoquinoline Alkaloid for the Development of Hypolipidemic Drugs

Curr Top Med Chem. 2020;20(28):2634-2647. doi: 10.2174/1568026620666200908165913.

Abstract

Berberine, as a representative isoquinoline alkaloid, exhibits significant hypolipidemic activity in both animal models and clinical trials. Recently, a large number of studies on the lipid-lowering mechanism of berberine and studies for improving its hypolipidemic activity have been reported, but for the most part, they have been either incomplete or not comprehensive. In addition, there have been a few specific reviews on the lipid-reducing effect of berberine. In this paper, the physicochemical properties, the lipid-lowering mechanism, and studies of the modification of berberine all are discussed to promote the development of berberine as a lipid-lowering agent. Subsequently, this paper provides some insights into the deficiencies of berberine in the study of lipid-lowering drug, and based on the situation, some proposals are put forward.

Keywords: Berberine; Bioavailability; Chemical modification; Cholesterol; Hypolipidemic activity; Physicochemical property; Triglyceride.

Publication types

  • Review

MeSH terms

  • Berberine / chemistry*
  • Berberine / pharmacology*
  • Humans
  • Hyperlipidemias / drug therapy*
  • Hypolipidemic Agents / chemical synthesis*
  • Hypolipidemic Agents / pharmacology*
  • Molecular Structure
  • Structure-Activity Relationship

Substances

  • Hypolipidemic Agents
  • Berberine